Metformin remains the go-to first line treatment for type 2 diabetes, while GLP-1 agonists offer a unique approach by stimulating brown fat activation. However, the conversation reveals a critical perspective on the over-prescription of insulin, emphasizing the need to address elevated insulin levels through dietary changes, particularly by cutting carbs. This shift in understanding challenges traditional views on fat consumption and highlights the complex relationship between diet and insulin sensitivity.
